1
Department of Pathology and Medical Oncology, University
Hospital Vrije Universiteit, 1007 MB Amsterdam,
The Netherlands
2
Gene Therapy Center, The University of Alabama at Birmingham
, 1824 6th Avenue South, Birmingham
, Alabama 35294-8627, USA
david.curiel@ccc.uab.edu
Many anti-tumor vaccines have failed in recent clinical trials because
they included the wrong patients and the wrong immune adjuvants — and
little was learned because the anti-tumor immune response was not carefully
monitored. A new tumor vaccine for lymphoma sets the stage for how future
trials should be carried out (pages 1171−1177).
